Back to Posters

Multi-gene panel testing increases yield of surgically-actionable results among breast cancer patients

Session:

#404284

Date:

Friday, May 4, 2018 6:00pm – 7:30pm

Conference:

—

Authors:

Amal Yussuf, Holly Laduca, Jessica Profato, Selvi Palaniappan, Tameron Harvell

TOP 12 ABSTRACT

Multigene Panel Testing (MGPT) increases the identification of surgically-actionable mutations for breast and other cancers, beyond BRCA1/2, by 6.45%.
With MGPT (excluding BRCA1/2) an additional 3.07% of patients were positive for PTEN or TP53, who may be considered for risk reducing mastectomy (RRM) as a treatment option.
Based on NCCN guidelines, our studies also shows that excluding BRCA1/2 an additional 54.22% of mutation carries could consider RRM in the context of their family history of breast cancer.

Abstract Poster